1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. - Akıllı, H.; Moore, R.G.; Marth, C.; Redondo, T. Diaz; Korach, J.; Stillie, A.; Baurain, J-F.; Mach, P.; Cadoo, K.; Bidzinski, M.; Ariyoshi, K.; Wu, X.; et al. (Annals of Oncology, 2025)